Literature DB >> 11315930

Pulmonary capillary endothelial dysfunction in early systemic sclerosis.

S E Orfanos1, E Psevdi, N Stratigis, D Langleben, J D Catravas, M Kyriakidis, H M Moutsopoulos, C Roussos, P G Vlachoyiannopoulos.   

Abstract

OBJECTIVE: Pulmonary capillary endothelium-bound angiotensin-converting enzyme (PCEB-ACE) activity is a sensitive and quantifiable index of endothelial function in vivo. Systemic sclerosis (SSc) is characterized by endothelial damage and excess collagen formation, causing mainly pulmonary hypertension (PH) in the limited cutaneous SSc (lcSSc) subset and interstitial lung disease with pulmonary interstitial fibrosis (PIF) in the diffuse cutaneous SSc (dcSSc) subset. This study was undertaken to investigate the hypothesis that PCEB-ACE activity is reduced early in SSc, in the absence of PH or PIF.
METHODS: Applying indicator-dilution techniques, we measured single-pass transpulmonary hydrolysis and percent metabolism (%M) of a synthetic ACE substrate and calculated functional capillary surface area (FCSA) in 25 SSc patients and 11 controls. Substrate hydrolysis and %M reflect ACE activity per capillary; FCSA reflects ACE activity per vascular bed.
RESULTS: PCEB-ACE activity was decreased in both SSc subsets. Among patients without PH, substrate hydrolysis and %M were decreased in patients with lcSSc and more profoundly in those with dcSSc; loss of FCSA normalized to body surface area (FCSA/BSA) was observed in dcSSc, but not in lcSSc. High-resolution computed tomography of the lung, performed in all SSc patients, revealed no correlation between substrate %M, hydrolysis, or FCSA/BSA and the degree of PIF; 5 dcSSc and 5 lcSSc patients with no detectable PIF exhibited decreases in hydrolysis and %M, while FCSA/BSA was decreased only in dcSSc.
CONCLUSION: Depression of PCEB-ACE activity, indicating pulmonary endothelial dysfunction, occurs early in SSc, in the absence of PH or PIF, and is more pronounced, at this early pulmonary disease stage, in dcSSc than in lcSSc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315930     DOI: 10.1002/1529-0131(200104)44:4<902::AID-ANR147>3.0.CO;2-9

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Reduced expression of angiotensin I-converting enzyme in caveolin-1 knockout mouse lungs.

Authors:  Nikolaos A Maniatis; Irina V Balyasnikova; Roman Metzger; Maricela Castellon; David J Visintine; David E Schwartz; Richard D Minshall; Sergei M Danilov
Journal:  Microvasc Res       Date:  2010-04-27       Impact factor: 3.514

2.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

Review 3.  Biomarkers of scleroderma lung disease: recent progress.

Authors:  Faye N Hant; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

4.  Angiotensin-converting enzyme gene insertion/deletion polymorphism in Korean patients with systemic sclerosis.

Authors:  Chung Il Joung; Yong Wook Park; Sook Kyoung Kim; Wan Sik Uhm; Tae Hwan Kim; Dae Hyun Yoo
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 5.  Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism.

Authors:  Cinzia Fatini; Serena Guiducci; Rosanna Abbate; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 7.  Novel biomarkers for pulmonary arterial hypertension.

Authors:  Anjum Anwar; Gregoire Ruffenach; Aman Mahajan; Mansoureh Eghbali; Soban Umar
Journal:  Respir Res       Date:  2016-07-20

8.  Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Authors:  David Langleben; Stylianos Orfanos
Journal:  Pulm Circ       Date:  2017-06-20       Impact factor: 3.017

9.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10

Review 10.  Endothelial pathomechanisms in acute lung injury.

Authors:  Nikolaos A Maniatis; Anastasia Kotanidou; John D Catravas; Stylianos E Orfanos
Journal:  Vascul Pharmacol       Date:  2008-07-29       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.